GLP-1 Skin Sensitivity, Rash and Itching: What the Labels Record

Skin that hurts to the touch and skin that itches or breaks out are two separate problems on a GLP‑1, and the labels count them in different places. The first is dysesthesia: burning, tingling or tenderness with nothing visible on the skin. It is a labeled, dose-related effect of semaglutide, reported by 2% of people on Wegovy 2.4 mg against 1% on placebo and by 22% on the 7.2 mg dose. On tirzepatide it is rare, under half a percent. The second is an allergic skin reaction: rash, hives, itching. Its clearest placebo-controlled signal is on the tirzepatide labels, where most of the 5% hypersensitivity rate on Zepbound was rash and itching. Itching that comes with a swollen face or throat, or with difficulty breathing, is an emergency on every label.

Which skin problem is it?

The sorting matters because the advice differs. An oversensitive patch of skin with no rash points toward the dose. A rash that spreads, or hives, points toward an immune reaction to the drug, which can change whether you should take it again.

Skin that hurts to the touch: dysesthesia

Wegovy is the only GLP‑1 label that gives dysesthesia its own paragraph. The term there is a bundle. For the 7.2 mg dose it pools eleven reported terms, among them allodynia (pain from a touch that should not hurt), hyperesthesia (heightened sensitivity), pain of skin, burning, and skin discomfort.^[1] That is the cluster people describe as skin that hurts under clothing, bedsheets or a shower spray.

The incidence of dysesthesia with WEGOVY increased with increasing dosage and drug levels in the blood.

— Wegovy prescribing information, section 6.1

The pattern is about dose and drug exposure more than brand. The published STEP UP trial gives the same gradient in raw counts: 230 of 1,004 people on 7.2 mg, 12 of 201 on 2.4 mg and one on placebo.^[5] Ozempic, whose top dose is 2 mg, gives no trial figure; its label lists dysesthesia among neurologic reactions reported after approval.^[3] Tirzepatide is rare but not zero. Mounjaro’s heart-outcomes trial in people with type 2 diabetes recorded it in 0.7%.^[4]

What happens next is the other half of the label paragraph, and it is detailed in what the 7.2 mg dose costs you. In short, most people whose prescriber paused, lowered or stopped the dose recovered, and recovery came faster when something was done; 18% of those affected at 7.2 mg had not recovered by the end of the trial, and 45% of those moved back up to 7.2 mg had it return.^[1] On the Wegovy tablet the figures are in Wegovy pill side effects.

What the case reports add

Clinicians have written up individual patients, and their accounts match the label’s dose pattern:

• Four patients at a VA health system, all on semaglutide 2.4 mg, developed skin tenderness as the dose went up. The two who stopped recovered. One of the two who kept going recovered after about four months. The authors rated each case a probable drug reaction and found no mechanism to explain it.^[6]
• Two people on tirzepatide had moderate to severe allodynia that appeared with dose increases and cleared once the drug was stopped.^[7]
• A single report described the same reaction on both semaglutide and tirzepatide and noted it can fade on its own after several weeks.^[8]
• An accidental 9.6 mg semaglutide dose, four times the patient’s weekly 2.4 mg after a pen-handling error, was followed two days later by burning skin across the body, with no nausea. It cleared within a week without treatment.^[9] What to do after a dosing error is in GLP-1 overdose.

A French analysis of the WHO’s global adverse-event database found semaglutide and tirzepatide reported disproportionately often with hyperesthesia, and semaglutide with dysesthesia and burning sensations.^[10] That is a reporting signal. It shows the complaint is being reported more than expected, not how often it happens or that the drug caused each case.

Why the drug would do this is not known. Nobody has shown a mechanism in people, and any explanation offered online is a guess. Tingling or numbness that stays in the hands and feet is a narrower question, covered in Ozempic and your hands and feet. Joint and muscle aches, which people often describe together with sore skin, are in GLP-1 joint pain and aches. Retatrutide, still in trials, shows the same signal at higher rates; see retatrutide’s evidence.

Itching and rash all over: the allergy column

Generalized itching, a rash on the trunk or limbs, or hives belong to a different row of the label: hypersensitivity. Here the order flips. Tirzepatide has the clearer trial signal.

The majority of the hypersensitivity reactions in trials were skin reactions (e.g., rash, itching).

— Zepbound prescribing information, section 6.1

On Zepbound, the extra risk sits mostly in reactions that start within a day of an injection: 2.1% against 0.4% on placebo. Reactions appearing later were almost as common on placebo.^[2] On Mounjaro, the diabetes brand of the same molecule, the overall rate was 3.2% against 1.7%.^[4] For anyone typing “Mounjaro itching all over”, that is the row that applies: a rash or itch that spreads beyond the injection site is counted as hypersensitivity, not as an injection site reaction.

Antibodies matter. People who developed antibodies against the drug had more allergic reactions on both molecules: 6.2% against 3% on Zepbound,^[2] and 16% against 7% in Wegovy’s adult trials.^[1]

Across the class, a 2026 meta-analysis of randomized trials found skin reactions elsewhere on the body were infrequent and not significantly raised against comparators, while injection site reactions were about three and a half times as likely.^[11] For most people, then, generalized rash on a GLP‑1 is uncommon. When it does happen, it is worth treating as a possible allergy rather than dry skin.

An allergy to one GLP‑1 does not always mean an allergy to all. In one case report, a woman who had tolerated tirzepatide up to 7.5 mg developed lip swelling and hives across her body after her first 10 mg dose. Skin testing was positive for tirzepatide and negative for semaglutide, and she went on to take semaglutide after a supervised test dose.^[12] That is one patient, under an allergist. The Zepbound and Wegovy labels both advise caution in anyone who has had anaphylaxis or angioedema on another GLP‑1, because nobody knows whether they are predisposed.^[1][2] Switching between GLP-1 drugs covers the mechanics.

Rare skin reactions in published case reports

Beyond the label tables, dermatologists have described a scattering of rarer reactions. Each is a single case or a handful, which shows that something can happen, not how likely it is.

• Bullous pemphigoid, an autoimmune blistering disease mostly seen in older adults, has been reported with semaglutide,^[13] dulaglutide^[14] and, in 2026, tirzepatide.^[15] The dulaglutide authors note that the diabetes drugs more often linked to it are the DPP‑4 inhibitors.^[14]
• Morbilliform drug eruption, a measles-like spreading rash, with tirzepatide.^[16]
• Cutaneous sarcoidosis: tender nodules on the trunk and limbs four weeks after starting semaglutide, which cleared after it was stopped. The same report describes sun-triggered hives returning five days after starting liraglutide in a woman free of them for over 20 years.^[17]
• A 2024 review collected other single reports, including eosinophilic panniculitis, and found that management usually meant stopping the drug.^[18]

Large-scale data point the other way for blistering disease. In a US records study that matched 169,630 people with type 2 diabetes starting a GLP‑1 to the same number starting a DPP‑4 inhibitor, GLP‑1 users had a lower rate of bullous pemphigoid (hazard ratio 0.61) and pemphigus, and a modestly higher rate of new psoriasis (1.19) over up to four years.^[19] It is observational, and the comparison is against another drug class, not against no treatment. For skin diseases where GLP‑1s are being studied as a help rather than a harm, see hidradenitis suppurativa and psoriasis.

What the FDA reporting database shows

The FDA Adverse Event Reporting System collects voluntary reports from patients, clinicians and manufacturers. Counts there reflect what people chose to report, how heavily a drug is prescribed and how much media attention a symptom gets. They are not rates, and a report does not establish that the drug caused the event.

These figures come from the openFDA interface to the database.^[22] Published analyses of the same database agree that skin complaints are a sizable share of what gets reported. One counted skin and injection-site reports together as 31% of all GLP‑1 reports, with the share higher for tirzepatide than semaglutide, and listed dysesthesia among the less common entries.^[21] Another found skin reactions were reported proportionally less often for GLP‑1s than for DPP‑4 inhibitors.^[20] Both are reporting signals, not measured risks.

When a skin reaction is an emergency

Serious hypersensitivity, including anaphylaxis and angioedema, is in the warnings of Wegovy and Zepbound,^[1][2] and of Ozempic and Mounjaro.^[3][4] All four make a prior serious reaction to the drug a contraindication. The patient Medication Guides list the signs that mean stopping the drug and getting help right away:

swelling of your face, lips, tongue or throat • problems breathing or swallowing • severe rash or itching • fainting or feeling dizzy • very rapid heartbeat

— Ozempic, Mounjaro and Zepbound Medication Guides, serious allergic reactions

If your skin is reacting

1. Look before you describe it. Is there a visible rash, raised welts or blisters, or does the skin look normal but hurt? Photograph anything visible. That one distinction steers your prescriber toward dose or toward allergy.
2. Note the timing. Did it start after a dose increase, within a day of an injection, or out of nowhere? Zepbound’s excess reactions clustered within a day of a dose,^[2] and dysesthesia tracked the dose on Wegovy.^[1]
3. Raise sore skin rather than waiting it out. On Wegovy 7.2 mg, events resolved faster when the prescriber acted than when nothing changed.^[1] Ask whether to hold the next step up.
4. Treat a spreading rash as a possible allergy. Contact the prescriber before the next dose. Blisters, peeling or sores in the mouth need same-day care.
5. Check the rest of the list. Mention anything else started around the same time, such as an antibiotic, a painkiller or a supplement. The rash may not be from the GLP‑1 at all.

Facial hollowing and loose skin after weight loss are a separate subject, covered in questions about skin on a GLP-1. How long side effects in general tend to last is in how long GLP-1 side effects last.